Otizmde Deneysel Terapötik Yaklaşımlar

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; American Psychiatric Association: Washington, DC, USA, 2013.

CDC Centers for Disease Control and Prevention. Available online: https://www.cdc.gov/ncbddd/autism/data.html (accessed on 5 March 2021).

Bilgiç A, Cöngöloğlu A (2009) Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamalari. Çocuk ve Gençlik Ruh Sağlığı Dergisi, 16:153-164

DeFilippis M (2018) The use of complementary alternative medicine in children and adolescents with autism spectrum disorder. Psychopharmacol Bull, 48:40-63.

Shuai B, Jin H, Lin Y, Duan R, Zhao N, Li Z, et al. (2020) Safety and efficacy of complementary and alternative medicine in the treatment of autism spectrum disorder: A protocol for systematic review and meta-analysis. Medicine (Baltimore), 99:e23128.

Hangül, Zehra, and Ali Evren Tufan. "Otizm spektrum bozukluğunda tamamlayıcı ve alternatif tedavilerin kullanımı." Psikiyatride Güncel Yaklaşımlar 14.2 (2022): 165-173.

Pusponegoro HD, Ismael S, Firmansyah A, Sastroasmoro S, Vandenplas Y. Gluten and casein supplementation does not increase symptoms in children with autism spectrum disorder. Acta Paediatr. 2015;104:e500–e505.

80. Elder JH, Shankar M, Shuster J, Theriaque D, Burns S, Sherrill L. The gluten-free, casein-free

diet in autism: results of a preliminary double blind clinical trial. J Autism Dev Disord. 2006;36(3): 413–420.

Johnson CR, Handen BL, Zimmer M, Sacco K, Turner K. Effects of gluten free/casein free diet in young children with autism: a pilot study. J Dev Phys Disabil. 2011;23:213–225.

Whiteley P, Haracopos D, Knivsberg AM, et al. The ScanBrit randomized, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders. Nutr Neurosci. 2010;13(2):87–100.

Knivsberg AM, Reichelt KL, Hoien T, Nodland M. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci. 2002;5(4):251–261.

Evangeliou A, Vlachonikolis I, Mihailidou H, et al. Application of a ketogenic diet in children with autistic behavior: pilot study. J Child Neurol. 2003;18(2):113–118.

Spilioti M, Evangeliou AE, Tramma D, et al. Evidence for treatable inborn errors of metabolism in a cohort of 187 Greek patients with autism spectrum disorder (ASD). Front Hum Neurosci. 2013;7:858.

Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioral therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res. 2012;21:700–709.

Wasdell MB, Jan JE, Bomben MM, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res. 2008;44:57–64.

Wright B, Sims D, Smart S, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behavior management strategies: a randomized controlled crossover trial. J Autism Dev Disord. 2011;41:175–184.

Wirojanan J, Jacquemont S, Diaz R, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009;5(2):145–150.

Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev. 2006;32(5):585–589.

Malow B, Adkins KW, McGrew SG, et al. Melatonin for sleep in children with autism: A controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord. 2012;42(8):1729–1737.

Campbell-McBride, Natasha. "Gut and psychologysyndrome." Journal of Orthomolecular Medicine 23.2 (2008): 90

Çıkılı Y, Deniz S, Çakal B. GAPS diyetinin otizm spektrum bozukluğu olan bireyler üzerindeki etkisinin incelenmesi. Ahmet Keleşoğlu Eğitim Fakültesi Dergisi. 2019;1(1):1-1.

Önal, S. ve Uçar, A. (2017). Otizm Spektrum Bozukluğu Tedavisinde Beslenme Yaklaşımları. Ankara Sağlık Bilimleri Dergisi, 6 (123), 179-194

Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry. 2012;17(4):389–401.

Bertoglio K, James SJ, Deprey L, Brule N, Hendren RL. Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. J Altern Complement Med. 2010;16(5):555–560.

28. Hendren RL, James SJ, Widjaja F, Lawton B, Rosenblatt A, Bent S. Randomized, placebo-controlled trial of methyl B12 for children with autism. J Child Adolesc Psychopharmacol. 2016;26(9):774–783.

Frye RE, Slattery J, Delhey L, et al. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Mol Psychiatry. 2016;00:1–10.

Frye RE, Melnyk S, Fuchs G, et al. Effectiveness of methylcobalamin and folinic acid treatment on adaptive behavior in children with autistic disorder is related to glutathione redox status. Autism Res Treat. 2013;2013:609–705.

Sun C, Zou M, Zhao D, Xia W, Wu L. Efficacy of folic acid supplementation in autistic children participating in structured teaching: an open-label trial. Nutrients. 2016;8(6):337.

Kern JK, Miller VS, Cauller L, Kendall R, Mehta J, Dodd M. Effectiveness of N,N Dimethylglycine in autism and pervasive developmental disorder. J Child Neurol. 2001;16(3):169–173.

57. Bolman WM, Richmond JA. A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. J Autism Dev Disord. 1999;29(3):191–194.

Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. J Altern Complement Med. 2004;10(6):1033–1039.

59. Adams JB, Audhya T, McDonough-Means S, et al. Effect of a vitamin/mineral supplement on children and adults with autism. BMC Pediatrics. 2011;11:111.

Azzam HME, Sayyah H, Youssef S, et al. Autism and vitamin D: and intervention study. Middle East Current Psychiatry. 2015;22:9–14.

Feng J, Shan L, Du L, et al. Clinical improvement following vitamin D3 supplementation in autism spectrum disorder. Nutr Neurosci. 2016. doi:10.1080/1028415X.2015.1123847. [Epub ahead of print].

Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry. 1993;17:765–774.

Nye C, Brice A. Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database. 2005;4:CD003497.

Murza KA, Pavelko SL, Malani MD, Nye C. Vitamin B6-magnesium treatment for autism: the current status of the research. Magnes Res. 2010;23(2):115–117.

Stewart PA, Hyman SL, Schmidt BL, et al. Dietary supplementation in children with autism spec- trum disorders: common, insufficient, and excessive. J Acad Nutr Diet. 2015;115(8):1237–1248.

Tomova A, Husarova V, Lakatosova S, et al. Gastrointestinal microbiota in children with autism in Slovakia. Physiol Behav. 2015;138:179–187.

Parracho HMRT, Gibson GR, Knott F, Bosscher D, Kleerebezem M, McCartney AL. A double-blind, placebo-controlled, crossover-designed probiotic feeding study in children diagnosed with autistic spectrum disorders. Int J Probiotics Prebiotics. 2010;5:69–74.

Kaluzna-Czaplinska J, Blaszczyk S. The level of arabinitol in autistic children after probiotic therapy. Nutrition. 2012;28:124–126.

Saad K, Eltayeb AA, Mohamad IL, et al. A randomized, placebo-controlled trial of digestive

enzymes in children with autism spectrum disorders. Clin Psychopharmacol Neurosci. 2015;13(2):188–193.

Munasinghe SA, Oliff C, Finn J, Wray JA. Digestive enzyme supplementation for autism spectrum disorders: a double-blind randomized controlled trial. J Autism Dev Disord. 2010;40:1131–1138.

Levy SE, Souders MC, Wray J, et al. Children with autistic spectrum disorders. I: Comparison of placebo and single dose of human synthetic secretin. Arch Dis Child. 2003;88:731–736.

Williams K, Wray JA, Wheeler DM. Intravenous secretin for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2012. Issue 4. Art. No: CD003495.

Bashir S, Al-Ayadhi LY. Effect of camel milk on thymus and activation-regulated chemokine in autistic children: double-blind study. Pediatr Res. 2014;75(4):559–563.

Al-Ayadhi LY, Elamin NE. Camel milk as a potential therapy as an antioxidant in autism spectrum disorder (ASD). Evid Based Complement Alternat Med. 2013. 602834.

Al-Ayadhi LY, Halepoto DM, Al-Dress AM, Mitwali Y, Zainah R. Behavioral benefits of camel milk in subjects with autism spectrum disorder. J Coll Physicians Surg Pak. 2015;25(11):819–823.

Wong VCN, Chen WX, Liu WL. Randomized controlled trial of electro-acupuncture for autism spectrum disorder. Altern Med Rev. 2010;15(2):136–146.

Uniform Data System for Medical Rehabilitation (UDSMR). WeeFIM System SM. Clinical Guide: Version 5.01. Buffalo, NY: University at Buffalo 2000.

Haley SM, Coster WJ, Ludlow LH, Haltiwanger JT, Andrellos PJ. Pediatric Evaluation of Disability Inventory: Development, Standardization, and Administration Manual, Version 1.0. Boston MA: PEDIResearch Group, 1992.

Roid GH, Miller LJ. Leiter International Performance Scale-Revised (Leiter-R). Wood Dale, IL; Stoelting Co: 1997.

Wong VCN, Sun JG. Randomized controlled trial of acupuncture versus sham acupuncture in autism spectrum disorder. J Altern Complement Med. 2010;16(5):545–553.

Griffiths R. The Abilities of Babies: A Study of Mental Measurements. London: University of London Press, 1954.

Reynell J. Reynell Language Developmental Scales. Windsor, UK: NFER-Nelson, 1976.

Lowe M, Costello AJ. Manual for Symbolic Play Test. Windsor, UK: NFER-Nelson, 1976.

Sampanthavivat M, Singkhwa W, Chaiyakul T, Karoonyawanich S, Ajpru H. Hyperbaric oxygen in the treatment of childhood autism: A randomized controlled trial. Diving Hyperb Med. 2012;42(3):128–133.

Rossignol DA, Rossignol LW, Smith S, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatr. 2009;9:21.

Granpeesheh D, Tarbox J, Dixon DR, Wilke AE, Allen MS, Bradstreet JJ. Randomized trial of hyperbaric oxygen therapy for children with autism. Res Autism Spectr Disord. 2010;4:268–275.

Lord C, Rutter M, DiLavore PC, Risi S. Autism Diagnostic Observation Schedule. Los Angeles: Western Psychological Services: 1999.

Green VA, Pituch KA, Itchon J, Choi A, O’Reilly M, Sigafoos J. Internet survey of treatments used by parents of children with autism. Res Dev Disabil. 2006;27:70–84.

Brown MJ, Willis T, Omalu B, Leiker R. Deaths resulting from hypocalcemia after administration of edentate disodium: 2003–2005. Pediatrics. 2006;118:534–536.

Adams JB, Baral M, Geis E, et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part A – medical results. BMC Clin Pharmacol. 2009;9:16.

Adams JB, Baral M, Geis E, et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B – behavioral results. BMC Clin Pharmacol. 2009;9:17.

Davis TN, O-Reilly M, Kang S, et al. Chelation treatment for autism spectrum disorders: a systematic review. Res Autism Spectr Disord. 2012;7:49–55.

James S, Stevenson SW, Silove N, Williams K. Chelation for autism spectrum disorder (ASD).Cochrane Database Syst Rev. 2015. Issue 5. Art. No.: CD010766.

Yatawara CJ, Einfeld SL, Hickie IB, Davenport TA, Guastella AJ. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Mol Psychiatry. 2016;21:1225–1231.

Guastella AJ, Gray KM, Rinehart NJ, et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. J Child Psychol Psychiatry. 2015;56(4):444–452.

Dadds MR, MacDonald E, Cauchi A, Williams K, Levy F, Brennan J. Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial. J Autism Dev Disord. 2014;44:521–531.

Gresham FM, Elliot SN. Social skills rating scale. Circle Pines, MN: American Guidance Service, 1990.

Maniram J, Karrim SBS, Oosthuizen F, Wiafe E. Pharmacological Management of Core Symptoms and Comorbidities of Autism Spectrum Disorder in Children and Adolescents: A Systematic Review. Neuropsychiatr Dis Treat. 2022 Aug 7;18:1629-1644.

Parker KJ, Oztan O, Libove RA, et al. A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Sci Transl Med. 2019;11(491).

Wu G, Lupton JR, Turner ND, Fang Y-Z, Yang S. Glutathione metabolism and its implications for health. The Journal of nutrition 2004;134:489-492.

Zhou N, Yang X, Huang A, Chen Z. The potential mechanism of N-acetylcysteine in treating COVID-19. Current pharmaceutical biotechnology 2021;22:1584-1590.

Liu X, Hu Z, Zhou H. [Retracted] N‐Acetylcysteine Improves Inflammatory Response in COPD Patients by Regulating Th17/Treg Balance through Hypoxia Inducible Factor‐1α Pathway. BioMed Research International 2021;2021:6372128.

Fu G, Xu Q, Qiu Y, et al. Suppression of Th17 cell differentiation by misshapen/NIK-related kinase MINK1. Journal of Experimental Medicine 2017;214:1453-1469.

Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biological psychiatry 2012;71:956-961.

Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders. BMC psychiatry 2013;13:1-7.

Nikoo M, Radnia H, Farokhnia M, Mohammadi M-R, Akhondzadeh S. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clinical neuropharmacology 2015;38:11-17.

Wink LK, Adams R, Wang Z, et al. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Molecular autism 2016;7:1-9.

Dean OM, Gray KM, Villagonzalo K-A, et al. A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Australian & New Zealand Journal of Psychiatry 2017;51:241-249.

Coghlan S, Horder J, Inkster B, Mendez MA, Murphy DG, Nutt DJ. GABA system dysfunction in autism and related disorders: from synapse to symptoms. Neuroscience & Biobehavioral Reviews 2012;36:2044-2055.

Osterweil EK, Krueger DD, Reinhold K, Bear MF. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. Journal of Neuroscience 2010;30:15616-15627.

Carlson GC. Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders. Pharmacology Biochemistry and Behavior 2012;100:850-854.

Sanchez-Ponce R, Wang L-Q, Lu W, Von Hehn J, Cherubini M, Rush R. Metabolic and pharmacokinetic differentiation of STX209 and racemic baclofen in humans. Metabolites 2012;2:596-613.

Lal R, Sukbuntherng J, Tai EH, et al. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. The Journal of pharmacology and experimental therapeutics 2009;330:911-921.

Aishworiya R, Valica T, Hagerman R, Restrepo B. An Update on Psychopharmacological Treatment of Autism Spectrum Disorder. Focus 2024;22:198-211.

Henderson C, Wijetunge L, Kinoshita MN, et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Science translational medicine 2012;4:152ra128-152ra128.

Berry-Kravis EM, Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Science translational medicine 2012;4:152ra127-152ra127.

Gundersen BB, T O’Brien W, Schaffler MD, et al. Towards preclinical validation of arbaclofen (R-baclofen) treatment for 16p11. 2 deletion syndrome. bioRxiv 2023.

Bahji A, Forth E, Nasar A, Waqas A, Hawken ER, Ayub M. Navigating agitation in neurodevelopmental disorders: A comparative study of pharmacotherapies via network meta-analysis in children and adults with autism spectrum disorder or intellectual disabilities. Journal of Psychopharmacology 2024:02698811241303654.

Roberts TP, Bloy L, Blaskey L, et al. A MEG study of acute arbaclofen (STX-209) administration. Frontiers in Integrative Neuroscience 2019;13:69.

Huang Q, Velthuis H, Pereira AC, et al. Exploratory evidence for differences in GABAergic regulation of auditory processing in autism spectrum disorder. Translational psychiatry 2023;13:320.

Veenstra-VanderWeele J, Cook EH, King BH, et al. Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial. Neuropsychopharmacology 2017;42:1390-1398.

Frye RE. Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder. Drug, healthcare and patient safety 2014:69-76.

Carlini EA. Research with marijuana in Brazil. SciELO Brasil, 2010: 53-54.

Zamberletti E, Gabaglio M, Parolaro D. The endocannabinoid system and autism spectrum disorders: insights from animal models. International journal of molecular sciences 2017;18:1916.

Pertwee RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addiction biology 2008;13:147-159.

Sagar DR, Jhaveri M, Chapman V. Targeting the cannabinoid system to produce analgesia. Behavioral Neurobiology of the Endocannabinoid System 2009:275-287.

Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. European Journal of Neuroscience 2003;17:2750-2754.

Piomelli D. The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience 2003;4:873-884.

Karhson DS, Krasinska KM, Dallaire JA, et al. Plasma anandamide concentrations are lower in children with autism spectrum disorder. Molecular autism 2018;9:1-6.

Pedrazzi JF, Ferreira FR, Silva-Amaral D, et al. Cannabidiol for the treatment of autism spectrum disorder: hope or hype? Psychopharmacology 2022;239:2713-2734.

Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives 2009;23:597-602.

Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life sciences 2011;89:165-170.

Walzer M, Bekersky I, Blum RA, Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2012;32:340-353.

Damkier P, Lassen D, Christensen MMH, Madsen KG, Hellfritzsch M, Pottegård A. Interaction between warfarin and cannabis. Basic & clinical pharmacology & toxicology 2019;124:28-31.

Arteaga-Henríquez G, Lugo-Marín J, Gisbert L, et al. Activation of the monocyte/macrophage system and abnormal blood levels of lymphocyte subpopulations in individuals with autism spectrum disorder: A systematic review and meta-analysis. International journal of molecular sciences 2022;23:14329.

Ahmad SF, Ansari MA, Nadeem A, et al. Involvement of CD45 cells in the development of autism spectrum disorder through dysregulation of granulocyte-macrophage colony-stimulating factor, key inflammatory cytokines, and transcription factors. International immunopharmacology 2020;83:106466.

Ceylan MF, Tural Hesapcioglu S, Yavas CP, Senat A, Erel O. Serum ischemia-modified albumin levels, myeloperoxidase activity and peripheral blood mononuclear cells in autism spectrum disorder (ASD). Journal of Autism and Developmental Disorders 2021;51:2511-2517.

Lamanna J, Meldolesi J. Autism Spectrum Disorder: Brain Areas Involved, Neurobiological Mechanisms, Diagnoses and Therapies. International Journal of Molecular Sciences 2024;25:2423.

Arteaga-Henriquez G, Gisbert L, Ramos-Quiroga JA. Immunoregulatory and/or anti-inflammatory agents for the management of core and associated symptoms in individuals with autism spectrum disorder: A narrative review of randomized, placebo-controlled trials. CNS drugs 2023;37:215-229.

Kierdorf K, Prinz M. Factors regulating microglia activation. Frontiers in cellular neuroscience 2013;7:44.

Ahmad SF, Zoheir KM, Ansari MA, et al. Dysregulation of Th1, Th2, Th17, and T regulatory cell-related transcription factor signaling in children with autism. Molecular neurobiology 2017;54:4390-4400.

Williams DM. Clinical pharmacology of corticosteroids. Respiratory care 2018;63:655-670.

Fu XQ, Cai JY, Li MJ. Prednisone may rebuild the immunologic homeostasis: Alteration of Th17 and Treg cells in the lymphocytes from rats' spleens after treated with prednisone‐containing serum. Molecular genetics & genomic medicine 2019;7:e00800.

Eddy JL, Krukowski K, Janusek L, Mathews HL. Glucocorticoids regulate natural killer cell function epigenetically. Cellular immunology 2014;290:120-130.

Malek M, Ashraf-Ganjouei A, Moradi K, Bagheri S, Mohammadi M-R, Akhondzadeh S. Prednisolone as adjunctive treatment to risperidone in children with regressive type of autism spectrum disorder: a randomized, placebo-controlled trial. Clinical Neuropharmacology 2020;43:39-45.

Brito AR, Vairo GdPT, Dias APBH, Olej B, Nascimento OJM, Vasconcelos MM. Effect of prednisolone on language function in children with autistic spectrum disorder: a randomized clinical trial. Jornal de pediatria 2021;97:22-29.

Duffy FH, Shankardass A, McAnulty GB, et al. Corticosteroid therapy in regressive autism: a retrospective study of effects on the Frequency Modulated Auditory Evoked Response (FMAER), language, and behavior. BMC neurology 2014;14:1-18.

Murugan S, Jakka P, Namani S, Mujumdar V, Radhakrishnan G. The neurosteroid pregnenolone promotes degradation of key proteins in the innate immune signaling to suppress inflammation. Journal of Biological Chemistry 2019;294:4596-4607.

Aggelakopoulou M, Kourepini E, Paschalidis N, et al. ERβ-dependent direct suppression of human and murine Th17 cells and treatment of established central nervous system autoimmunity by a neurosteroid. The Journal of Immunology 2016;197:2598-2609.

Ayatollahi A, Bagheri S, Ashraf-Ganjouei A, Moradi K, Mohammadi M-R, Akhondzadeh S. Does pregnenolone adjunct to risperidone ameliorate irritable behavior in adolescents with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial? Clinical neuropharmacology 2020;43:139-145.

Asadabadi M, Mohammadi M-R, Ghanizadeh A, et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology 2013;225:51-59.

Villa V, Thellung S, Bajetto A, et al. Novel celecoxib analogues inhibit glial production of prostaglandin E2, nitric oxide, and oxygen radicals reverting the neuroinflammatory responses induced by misfolded prion protein fragment 90-231 or lipopolysaccharide. Pharmacological Research 2016;113:500-514.

Singh S, Khanna D, Kalra S. Minocycline and doxycycline: more than antibiotics. Current Molecular Pharmacology 2021;14:1046-1065.

Campbell JH, Burdo TH, Autissier P, et al. Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV neuroAIDS. PloS one 2011;6:e18688.

Florou DT, Mavropoulos A, Dardiotis E, et al. Tetracyclines diminish in vitro IFN-γ and IL-17-producing adaptive and innate immune cells in multiple sclerosis. Frontiers in Immunology 2021;12:739186.

Ghaleiha A, Alikhani R, Kazemi M-R, et al. Minocycline as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind placebo-controlled trial. Journal of child and adolescent psychopharmacology 2016;26:784-791.

Ruhee RT, Suzuki K. The integrative role of sulforaphane in preventing inflammation, oxidative stress and fatigue: A review of a potential protective phytochemical. Antioxidants 2020;9:521.

Singh K, Connors SL, Macklin EA, et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proceedings of the National Academy of Sciences 2014;111:15550-15555.

Momtazmanesh S, Amirimoghaddam‐Yazdi Z, Moghaddam HS, Mohammadi MR, Akhondzadeh S. Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double‐blind, placebo‐controlled clinical trial. Psychiatry and clinical neurosciences 2020;74:398-405.

Zimmerman AW, Singh K, Connors SL, et al. Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. Molecular autism 2021;12:38.

Giacobbe J, Benoiton B, Zunszain P, Pariante CM, Borsini A. The anti-inflammatory role of omega-3 polyunsaturated fatty acids metabolites in pre-clinical models of psychiatric, neurodegenerative, and neurological disorders. Frontiers in Psychiatry 2020;11:450833.

Chehimi M, Ward R, Pestel J, et al. Omega‐3 polyunsaturated fatty acids inhibit IL‐17A secretion through decreased ICAM‐1 expression in T cells co‐cultured with adipose‐derived stem cells harvested from adipose tissues of obese subjects. Molecular Nutrition & Food Research 2019;63:1801148.

Bent S, Hendren RL, Zandi T, et al. Internet-based, randomized, controlled trial of omega-3 fatty acids for hyperactivity in autism. Journal of the American Academy of Child & Adolescent Psychiatry 2014;53:658-666.

Bent S, Bertoglio K, Ashwood P, Bostrom A, Hendren RL. A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. Journal of autism and developmental disorders 2011;41:545-554.

Mankad D, Dupuis A, Smile S, et al. A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism. Molecular autism 2015;6:1-11.

KURKIN, Denis V., et al. Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. PLoS One, 2021, 16.7: e0254493.

Zykov VP, Serebrennikova EB, Panchenko TN, et al. Rezul'taty mul'titsentrovogo issledovaniia éffektivnosti primeneniia korteksina pri kognitivnykh disfunktsiiakh u deteĭ [Results of a multicenter study on the efficacy of cortexin in treatment of cognitive dysfunction in children]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):27-31. Russian. doi: 10.17116/jnevro20181183127-31. PMID: 29652302.

Degtyareva VG, Drobyshev VA, Poteryaeva EL. Effektivnost' reabilitatsionnykh meropriyatii s primeneniem lekarstvennogo preparata Korteksin u detei s psikhonevrologicheskoi patologiei [The effectiveness of rehabilitation measures using the drug Cortexin in children with neuropsychiatric pathology]. Zh Nevrol Psikhiatr Im S S Korsakova. 2024;124(12):86-92. Russian. doi: 10.17116/jnevro202412412186. PMID: 39731376.

FERNELL, Elisabeth; GUSTAFSSON, Peik; GILLBERG, Christopher. Bumetanide for autism: Open‐label trial in six children. Acta paediatrica, 2021, 110.5: 1548-1553.

Wang, T., Shan, L., Miao, C., Xu, Z., & Jia, F. (2021). Treatment effect of bumetanide in children with autism spectrum disorder: a systematic review and meta-analysis. Frontiers in Psychiatry, 12, 751575.

Hough, D., Mao, A. R., Aman, M., Lozano, R., Smith-Hicks, C., Martinez-Cerdeno, V., ... & Findling, R. L. (2023). Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder. Annals of General Psychiatry, 22(1), 45.

Qiu, J., Kong, X., Li, J., Yang, J., Huang, Y., Huang, M., ... & Kong, J. (2021). Transcranial direct current stimulation (tDCS) over the left dorsal lateral prefrontal cortex in children with autism spectrum disorder (ASD). Neural plasticity, 2021(1), 6627507.